BridgeBio Pharma (BBIO) Change in Account Payables (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Change in Account Payables data on file, last reported at -$7.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables fell 140.81% year-over-year to -$7.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (down 92.53% YoY), and the FY2025 full-year result was $26.6 million, up 1659.85% from the prior year.
• Change in Account Payables slipped to -$7.2 million in Q1 2026, from $17.5 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $17.6 million in Q1 2025 to a low of -$7.4 million in Q3 2025.
• A 5-year average of $1.4 million and a median of -$1.1 million in 2025 frame the typical range for Change in Account Payables.
• Peak annual rise in Change in Account Payables reached 5061.41% in 2024, while the deepest fall reached 618.88% in 2024.
• Tracing BBIO's Change in Account Payables over 5 years: stood at $1.4 million in 2022, then surged by 349.42% to $6.2 million in 2023, then plunged by 160.56% to -$3.7 million in 2024, then surged by 567.96% to $17.5 million in 2025, then slumped by 140.91% to -$7.2 million in 2026.
• Business Quant data shows BBIO's Change in Account Payables at -$7.2 million in Q1 2026, $17.5 million in Q4 2025, and -$7.4 million in Q3 2025.